TY - JOUR
T1 - To beta block or not to beta block; that is the question
AU - Ince, Can
PY - 2015
Y1 - 2015
N2 - The fast-acting beta-1 blocker esmolol has been the center of attention since the landmark article by Morrelli and colleagues suggesting that, in patients with sepsis, reducing heart rate by administering esmolol can result in a survival benefit. However, the use of esmolol for the treatment of sepsis and the underlying mechanism responsible for this benefit remain controversial. This commentary discusses the study by Jacquet-Lagreze and colleagues, who in a pig model of sepsis tested the hypothesis that administration of esmolol to reduce heart rate may correct sepsis-induced sublingual and gut microcirculatory alterations which are known to be associated with adverse outcome
AB - The fast-acting beta-1 blocker esmolol has been the center of attention since the landmark article by Morrelli and colleagues suggesting that, in patients with sepsis, reducing heart rate by administering esmolol can result in a survival benefit. However, the use of esmolol for the treatment of sepsis and the underlying mechanism responsible for this benefit remain controversial. This commentary discusses the study by Jacquet-Lagreze and colleagues, who in a pig model of sepsis tested the hypothesis that administration of esmolol to reduce heart rate may correct sepsis-induced sublingual and gut microcirculatory alterations which are known to be associated with adverse outcome
U2 - https://doi.org/10.1186/s13054-015-1059-6
DO - https://doi.org/10.1186/s13054-015-1059-6
M3 - Editorial
C2 - 26400614
SN - 1364-8535
VL - 19
SP - 339
JO - Critical care (London, England)
JF - Critical care (London, England)
IS - 1
ER -